# EDGAR Filing Document

**Accession Number:** 0000318154
**File Stem:** 0000318154-26-000114
**Filing Date:** 2026-6
**Character Count:** 41770
**Document Hash:** d6f0f1d78c7b62f819f392a5ab9b7a6c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000318154-26-000114.hdr.sgml**: 20260611

**ACCESSION NUMBER**: 0000318154-26-000114

**CONFORMED SUBMISSION TYPE**: 11-K

**PUBLIC DOCUMENT COUNT**: 31

**CONFORMED PERIOD OF REPORT**: 20251231

**FILED AS OF DATE**: 20260611

**DATE AS OF CHANGE**: 20260611

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AMGEN INC
- **CENTRAL INDEX KEY:** 0000318154
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 953540776
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 11-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37702
- **FILM NUMBER:** 261083377

**BUSINESS ADDRESS:**
- **STREET 1:** ONE AMGEN CENTER DRIVE
- **CITY:** THOUSAND OAKS
- **STATE:** CA
- **ZIP:** 91320
- **BUSINESS PHONE:** (805)447-1000

**MAIL ADDRESS:**
- **STREET 1:** ONE AMGEN CENTER DRIVE
- **CITY:** THOUSAND OAKS
- **STATE:** CA
- **ZIP:** 91320

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AMGEN
- **DATE OF NAME CHANGE:** 19870305

?xml version='1.0' encoding='ASCII'? amgn-20260611

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington D.C. 20549**

**FORM 11-K**

**(Mark One)**

---

| | |
|:---|:---|
| 🗷 | **ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** |

---

**For the fiscal year ended December 31, 2025** 

**OR**

---

| | |
|:---|:---|
| ◻ | **TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** |

---

**Commission file number 001-37702**

**RETIREMENT AND SAVINGS PLAN FOR**

**AMGEN MANUFACTURING LIMITED LLC**

State Road 31, Kilometer 24.6, Juncos, Puerto Rico 00777

(Full title and address of the plan)

**AMGEN INC.**

(Name of issuer of the securities held)

---

| | |
|:---|:---|
| **One Amgen Center Drive,** | **91320-1799** |
| **Thousand Oaks, California** | (Zip Code) |
| (Address of principal executive offices) | |

---

------

**Retirement and Savings Plan for**

**Amgen Manufacturing Limited LLC**

**Audited Financial Statements**

**and Supplemental Schedule**

**Year Ended December 31, 2025**

**Contents**

---

| | |
|:---|:---|
| <u>[Report of Independent Registered Public Accounting Firm](#idfc018afaf984626a8a22195a17135ee_7)</u> | <u>[1](#idfc018afaf984626a8a22195a17135ee_7)</u> |
| **Audited Financial Statements:** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Statements of Net Assets Available for Benefits at December 31, 2025 and 2024](#idfc018afaf984626a8a22195a17135ee_10)</u> | <u>[2](#idfc018afaf984626a8a22195a17135ee_10)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Statement of Changes in Net Assets Available for Benefits for the year ended December 31, 2025](#idfc018afaf984626a8a22195a17135ee_13)</u> | <u>[3](#idfc018afaf984626a8a22195a17135ee_13)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Notes to Financial Statements](#idfc018afaf984626a8a22195a17135ee_16)</u> | <u>[4](#idfc018afaf984626a8a22195a17135ee_16)</u> |
| **Supplemental Schedule:** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Schedule of Assets (Held at End of Year)](#idfc018afaf984626a8a22195a17135ee_34)</u> | <u>[10](#idfc018afaf984626a8a22195a17135ee_34)</u> |
| <u>[Index to Exhibit](#idfc018afaf984626a8a22195a17135ee_37)</u> | <u>[14](#idfc018afaf984626a8a22195a17135ee_37)</u> |
| <u>[Signatures](#idfc018afaf984626a8a22195a17135ee_40)</u> | <u>[15](#idfc018afaf984626a8a22195a17135ee_40)</u> |

---

------

**Report of Independent Registered Public Accounting Firm**

To the Plan Participants and the Plan Administrator of the Retirement and Savings Plan for Amgen Manufacturing Limited LLC

**Opinion on the Financial Statements**

We have audited the accompanying statements of net assets available for benefits of the Retirement and Savings Plan for Amgen Manufacturing Limited LLC (the Plan) as of December 31, 2025 and 2024, and the related statement of changes in net assets available for benefits for the year ended December 31, 2025, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan at December 31, 2025 and 2024, and the changes in its net assets available for benefits for the year ended December 31, 2025, in conformity with U.S. generally accepted accounting principles.

**Basis for Opinion**

These financial statements are the responsibility of the Plan's management. Our responsibility is to express an opinion on the Plan's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Plan is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Plan's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

**Supplemental Schedule Required by ERISA**

The accompanying supplemental schedule of assets (held at end of year) as of December 31, 2025, (referred to as the "supplemental schedule"), has been subjected to audit procedures performed in conjunction with the audit of the Plan's financial statements. The information in the supplemental schedule is the responsibility of the Plan's management. Our audit procedures included determining whether the information reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental schedule. In forming our opinion on the information, we evaluated whether such information, including its form and content, is presented in conformity with the Department of Labor's Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, the information is fairly stated, in all material respects, in relation to the financial statements as a whole.

/s/ ERNST & YOUNG LLP

We have served as the Plan's auditor since 1992.

Los Angeles, California

June 11, 2026

------

**Retirement and Savings Plan for Amgen Manufacturing Limited LLC**

**Statements of Net Assets Available for Benefits**

---

| | | |
|:---|:---|:---|
| | **December 31,** | **December 31,** |
| | **2025** | **2024** |
| **Assets** |  |  |
| &nbsp;&nbsp;&nbsp;Investments at fair value | $911174783 | $762010202 |
| &nbsp;&nbsp;&nbsp;Notes receivable from participants | 19422412 | 18107898 |
| &nbsp;&nbsp;&nbsp;Other – principally due from broker | 235835 | 302276 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total assets | 930833030 | 780420376 |
| **Liabilities** |  |  |
| &nbsp;&nbsp;&nbsp;Other – principally due to broker | 208714 | 332225 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 208714 | 332225 |
| **Net assets available for benefits** | $930624316 | $780088151 |

---

*See accompanying notes.*

------

**Retirement and Savings Plan for Amgen Manufacturing Limited LLC**

**Statement of Changes in Net Assets Available for Benefits**

---

| | |
|:---|:---|
| | **Year Ended December 31,**<br>**2025** |
| Additions to (deductions from) net assets: |  |
| &nbsp;&nbsp;&nbsp;Employer contributions | $22642145 |
| &nbsp;&nbsp;&nbsp;Participant contributions | 20015238 |
| &nbsp;&nbsp;&nbsp;Rollover contributions | 1111853 |
| &nbsp;&nbsp;&nbsp;Interest and dividend income | 6491598 |
| &nbsp;&nbsp;&nbsp;Net realized/unrealized gains | 124470752 |
| &nbsp;&nbsp;&nbsp;Interest income on notes receivable from participants | 1428550 |
| &nbsp;&nbsp;&nbsp;Benefits paid | (25178261) |
| &nbsp;&nbsp;&nbsp;Investment and administrative fees | (445710) |
| Net increase | 150536165 |
| Net assets available for benefits at beginning of year | 780088151 |
| Net assets available for benefits at end of year | $930624316 |

---

*See accompanying notes.*

------

**Retirement and Savings Plan for Amgen Manufacturing Limited LLC**

**Notes to Financial Statements**

**December 31, 2025** 

**1. Description of the Plan**

The following is a description of the Retirement and Savings Plan for Amgen Manufacturing Limited LLC (the Plan). The description below provides only general information, and accordingly, participants should refer to the Plan document for a more complete description of the Plan's provisions.

*General*

The Plan was established effective January 1, 2002, was amended and restated effective January 1, 2017, and was subsequently amended with the most recent amendment effective on or prior to December 31, 2025 adopted on June 7, 2024. The Plan was subsequently amended and restated effective January 1, 2026. The Plan is a defined contribution plan covering substantially all Puerto Rico resident employees of Amgen Manufacturing Limited LLC (the Company), a wholly owned subsidiary of Amgen Inc. (Amgen). The Plan is intended to qualify under Section 1081.01 of the Puerto Rico Internal Revenue Code of 2011, as amended (the PR Code) (see Note 4, *Income Tax Status*) and section 407(d)(3)(A) of the Employee Retirement Income Security Act of 1974 (ERISA).

*Contributions*

Subject to certain limitations (as defined in the Plan), participants may elect to contribute up to 30% of their eligible compensation in pre-tax contributions and after-tax contributions or a combination of these types of contributions (together, Individual Contributions). A participant's pre-tax contributions are subject to the PR Code and Plan limitations and could not exceed $15,000 in 2025. Participants may elect to contribute after-tax contributions beginning January 1 of the year following the year the participant was hired. Participant after-tax contributions are subject to the PR Code and Plan limitations and could not exceed $1,500 in 2025. Unless an employee has voluntarily enrolled in the Plan or has declined to participate in the Plan within the first 30 days of employment, all newly eligible participants are automatically enrolled in the Plan, and contributions equal to 5% of their eligible compensation are withheld and contributed to the Plan as pre-tax contributions; such contributions are automatically increased by 1% per year until their contributions reach 10% of their eligible compensation. Participants may elect to adjust, cease or resume their Individual Contributions at any time.

Participants who are at least age 50 by the close of the Plan year may also elect to make certain additional pre-tax Individual Contributions, referred to as catch-up contributions, that are subject to the PR Code and Plan limitations and could not exceed $1,500 in 2025. Participants may also contribute pre-tax and after-tax amounts representing distributions from certain other retirement plans qualified in Puerto Rico, referred to as rollover contributions (as defined in the Plan).

Each pay period, the Company makes a non-elective contribution for all eligible participants, whether or not they have elected to make Individual Contributions to the Plan, equal to 4% of each participant's eligible compensation up to a maximum of $14,000 in 2025 (Core Contributions). In addition, the Company makes a contribution equal to amounts contributed by the participant as pre-tax contributions, including catch-up contributions, of up to 5% of eligible compensation (Matching Contributions). Matching Contributions could not exceed $15,000 in 2025 (or $16,500 for catch-up eligible participants).

Participants select the investments in which their Individual Contributions, including their Core Contributions and Matching Contributions (collectively, Company Contributions), are to be invested, electing among various alternatives, including Amgen common stock (Amgen stock). Participants may direct a maximum of 20% of contributions to be invested in Amgen stock. In addition, participants may transfer amounts among the investment options at any time, subject to certain limitations. Notwithstanding the foregoing, if 20% or more of the value of a participant's Plan account is invested in Amgen stock, the Plan document provides that no transfers from other investment options can be made to invest in Amgen stock.

The accounts of participants who have not made an investment election are allocated to investments under a qualified default investment alternative, which is intended to be compliant with ERISA regulations. At any time, participants may elect to alter the investments in their accounts made under a qualified default investment alternative.

*Vesting and Forfeitures*

Participants are immediately vested with respect to their Individual Contributions and Matching Contributions and earnings and losses (hereafter referred to as earnings) thereon. Participants hired prior to January 1, 2020, are also immediately vested with respect to their Core Contributions and earnings thereon. Participants hired on or after January 1, 2020, vest in full with respect to their Core Contributions and earnings thereon after three years of service, as defined by the terms of the Plan, or upon

------

**Retirement and Savings Plan for Amgen Manufacturing Limited LLC**

**Notes to Financial Statements (continued)**

reaching age 65 while employed by the Company, if earlier. If a participant ceases to be an employee before fully vesting in their account, the non-vested Core Contributions and earnings thereon of the participant's account will be treated as a forfeiture, as defined by the terms of the Plan, on the earlier of (a) the date the participant incurs a five-year break in service, as defined by the terms of the Plan or, (b) the date the participant receives a distribution of the entire vested portion of their account. Forfeitures are applied, in accordance with Plan provisions, to reduce Core or Matching Contributions, to reinstate forfeitures of reemployed participants, to reinstate the accounts of lost participants or beneficiaries (as defined in the Plan), to reduce Plan administrative expenses for the current or immediately following Plan year, and/or for any other purpose permitted under federal regulations or other applicable authority.

*Participant Accounts*

Each participant's account is credited with: (a) the participant's Individual Contributions; (b) an allocation of Company Contributions; and (c) earnings. The benefit to which a participant is entitled is the benefit that can be provided from the participant's account.

*Plan Investments*

Plan participants can invest in seven different asset classes as well as Amgen stock or can actively manage their account under a self-directed brokerage arrangement in which a wider array of investment options are available. The value of an investment in an asset class is determined by its underlying investment vehicles, which may include one or more of the following: mutual funds, collective trust funds and portfolios, which are separately managed exclusively for the benefit of Plan participants and their beneficiaries (separately managed portfolios). The separately managed portfolios are composed primarily of investments in publicly traded common and preferred stocks. The asset classes are designed to provide participants with choices among a variety of investment objectives.

*Payments of Benefits*

Subject to Plan limitations, upon termination of employment, including termination due to disability (as defined in the Plan) or retirement, a participant may elect to receive a full or partial distribution of his or her account balance in: (a) a single payment in cash; (b) a single distribution in full shares of Amgen stock (with any fractional shares paid in cash); (c) a single distribution paid in a combination of cash and full shares of Amgen stock; or (d) a rollover distribution to an eligible retirement plan.

Participants may also elect to maintain their account balance in the Plan subsequent to termination of employment, provided that their account balance is greater than $1,000.

If a participant dies before receiving the value of his or her account balance, the participant's beneficiary may elect to receive the distribution of remaining funds from among the alternatives described above, subject to certain Plan limitations.

No withdrawals may be made from the Plan while a participant continues to be employed by the Company except in certain circumstances including, but not limited to, financial hardship, disability and attainment of age 59 1/2.

*Notes Receivable from Participants*

Subject to certain restrictions, a participant can have up to two loans outstanding at any one time from his or her Plan account with a combined maximum loan amount that may not exceed the lesser of: (a) 50% of the participant's account balance or (b) $50,000 less certain adjustments, as applicable (as defined in the Plan). A participant's loan is secured by his or her Plan account balance. Loans bear interest at fixed rates which, until changed by the Company, are based on the prime rate plus one percentage point as published in The Wall Street Journal, determined as of the last day of the calendar quarter preceding origination or such other rate as may be required by law. Loans are generally payable in installments over periods ranging from one to five years, unless the loan is used to acquire a principal residence for which the term of the loan may be up to 20 years. Principal and interest payments are allocated to the participant's account.

*Plan Termination*

Although it has not expressed any intent to do so, the Company has the right under the Plan to terminate the Plan subject to the provisions of ERISA. Upon termination, participants would become fully vested in Core Contributions and receive distributions of their account balances.

------

**Retirement and Savings Plan for Amgen Manufacturing Limited LLC**

**Notes to Financial Statements (continued)**

*Trustee and Custodians*

Banco Popular de Puerto Rico is the Plan's trustee. Bank of America, N.A. is the Plan's custodian with respect to the self-directed brokerage arrangement and the Amgen common stock fund. The Northern Trust Company, NA (Northern) is the Plan's custodian with respect to the asset classes.

**2. Summary of Significant Accounting Policies**

*Basis of Accounting*

The accompanying financial statements are prepared on the accrual basis of accounting. Benefits to participants are recorded when paid.

*Fair Value Measurement*

The investments of the Plan are reported at fair value. Fair value is generally defined as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date (see Note 3, *Fair Value Measurements*).

*Investment Income and Losses*

Dividend income is recognized on the ex-dividend date, and interest income is recorded on an accrual basis. Unrealized gains and losses on investments are measured by the change in the difference between the fair value and cost of the securities held at the beginning of the year (or date purchased if acquired during the Plan year) and the end of the year. Realized gains and losses from security transactions are recorded based on the weighted-average cost of securities sold.

*Notes Receivable from Participants*

Notes receivable from participants are carried at their unpaid balance plus accrued but unpaid interest, as applicable.

*Due from/to Brokers*

Purchases and sales of investments are recorded on a trade-date basis. Amounts due from and due to brokers arise from unsettled sale and purchase transactions, respectively.

*Use of Estimates*

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the financial statements, accompanying notes and supplemental schedule. Actual results could differ from those estimates.

*Risks and Uncertainties*

The Plan provides for investment options representing varied combinations of equities (including Amgen stock), fixed income, and other investments. Investments, in general, particularly in securities, are exposed to various risks, such as interest rate, inflation, market and credit risks, among others. Market risk includes global events which could impact the value of investments, including securities, such as a pandemic or international conflict. Due to the level of risk associated with certain investments, including securities, it is at least reasonably possible that changes in the values of the Plan's investments, including securities, will occur in the near term and that such changes could materially affect participant account balances and the amounts reported in the Plan's financial statements.

**3. Fair Value Measurements**

The Plan uses various valuation approaches in determining the fair value of investments within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the investment based on market data obtained from independent sources. Unobservable inputs are inputs that reflect assumptions about the inputs that market participants would use in pricing the investment and are developed based on the best information available in the circumstances.

------

**Retirement and Savings Plan for Amgen Manufacturing Limited LLC**

**Notes to Financial Statements (continued)**

The fair value hierarchy is divided into three levels based on the source of inputs as follows:

Level 1 – Valuations based on unadjusted quoted prices in active markets for identical investments that the Plan has the ability to access

Level 2 – Valuations for which all significant inputs are observable, either directly or indirectly, other than Level 1 inputs

Level 3 – Valuations based on inputs that are unobservable and significant to the overall fair value measurement

The availability of observable inputs can vary among the various types of investments. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used for measuring fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level of input used that is significant to the overall fair value measurement.

The following fair value hierarchy tables present information about each major class/category of the Plan's investments measured at fair value:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Fair value measurements at December 31, 2025, using** | **Fair value measurements at December 31, 2025, using** | **Fair value measurements at December 31, 2025, using** | **Fair value measurements at December 31, 2025, using** |
| | **Quoted prices<br>in active<br>markets for<br>identical assets<br>(Level 1)** | **Significant<br>other<br>observable<br>inputs<br>(Level 2)** | **Significant<br>unobservable<br>inputs<br>(Level 3)** | **Total** |
| Amgen stock | $126196526 | $— | $— | $126196526 |
| Cash and cash equivalents | 339411 |  |  | 339411 |
| Collective trust funds |  | 722136732 |  | 722136732 |
| Common and preferred stocks | 8175678 |  |  | 8175678 |
| Mutual funds | 27612784 |  |  | 27612784 |
| Self-directed brokerage accounts | 26713652 |  |  | 26713652 |
| Total investments at fair value | $189038051 | $722136732 | $— | $911174783 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Fair value measurements at December 31, 2024, using** | **Fair value measurements at December 31, 2024, using** | **Fair value measurements at December 31, 2024, using** | **Fair value measurements at December 31, 2024, using** |
| | **Quoted prices<br>in active<br>markets for<br>identical assets<br>(Level 1)** | **Significant<br>other<br>observable<br>inputs<br>(Level 2)** | **Significant<br>unobservable<br>inputs<br>(Level 3)** | **Total** |
| Amgen stock | $100973506 | $— | $— | $100973506 |
| Cash and cash equivalents | 43702 |  |  | 43702 |
| Collective trust funds |  | 577297941 |  | 577297941 |
| Common and preferred stocks | 47870415 |  |  | 47870415 |
| Mutual funds | 16198902 |  |  | 16198902 |
| Self-directed brokerage accounts | 19625736 |  |  | 19625736 |
| Total investments at fair value | $184712261 | $577297941 | $— | $762010202 |

---

The fair values of substantially all common stocks (including Amgen stock), preferred stocks, mutual funds and underlying investments of self-directed brokerage accounts are valued using quoted market prices in active markets with no valuation adjustment.

Collective trust funds represent interests in pooled investment vehicles designed typically for collective investment of employee benefit trusts. The fair values of these investments are determined by reference to the net asset value per unit provided by the fund managers as the basis for current transactions.

------

**Retirement and Savings Plan for Amgen Manufacturing Limited LLC**

**Notes to Financial Statements (continued)**

**4. Income Tax Status**

The Plan received an opinion letter from the Puerto Rico Treasury Department (PRTD) dated February 26, 2018, with an effective date of January 1, 2017, stating that the Plan meets the requirements of Section 1081.01 of the PR Code and the regulations thereunder, and, therefore the related trust forming part of the Plan is exempt from taxation. Subsequently, seven amendments were made to the Plan, and the Plan received letters from the PRTD stating the PRTD has no objection to any of the seven amendments. Once qualified, the Plan is required to operate in conformity with the PR Code to maintain its qualification.

For taxable year 2025, the Company believes the Plan satisfied, and operated in compliance with, the applicable requirements of the PR Code and therefore believes that the Plan, as amended, is qualified and the related trust is tax exempt. The Company has indicated that it currently intends to continue to take the necessary steps, if any, to maintain the Plan's compliance with the applicable requirements of the PR Code.

**5. Party-in-Interest Transactions**

Parties-in-interest are certain entities defined under Department of Labor regulations, including Amgen, and other parties that provide services to the Plan, such as the trustees, custodians and investment managers. The Plan pays the custodians certain administrative and investment management fees, and the Company pays certain administrative fees on behalf of the Plan. The Plan invests in collective trust funds managed by Northern, certain of the Plan's investment managers and other third parties and may invest in securities of entities that are parties-in-interest. The Plan also invests in shares of common stock of Amgen and receives dividends on those shares. Notes receivable from participants are also considered party-in-interest transactions.

------

**Retirement and Savings Plan for Amgen Manufacturing Limited LLC**

**Notes to Financial Statements (continued)**

**6. Reconciliation of Financial Statements to the Form 5500**

The reconciliation of net assets available for benefits per the financial statements to the Form 5500 consisted of the following:

---

| | | |
|:---|:---|:---|
| | **December 31,** | **December 31,** |
| | **2025** | **2024** |
| Net assets available for benefits per the financial statements | $930624316 | $780088151 |
| Amounts allocated to withdrawing participants |  | (9000) |
| Deemed loans | (790729) | (887701) |
| &nbsp;&nbsp;&nbsp;Net assets per the Form 5500 | $929833587 | $779191450 |

---

The following is a reconciliation of expenses per the financial statements to the Form 5500:

---

| | |
|:---|:---|
| | **Year Ended December 31, 2025** |
| Benefits paid | $(25178261) |
| Investment and administrative fees | (445710) |
| &nbsp;&nbsp;&nbsp;Total expenses per the financial statements | (25623971) |
| Amounts allocated to withdrawing participants at December 31, 2024 | 9000 |
| Amounts allocated to withdrawing participants at December 31, 2025 |  |
| Deemed loans at December 31, 2024 | 887701 |
| Deemed loans at December 31, 2025 | (790729) |
| &nbsp;&nbsp;&nbsp;Total expenses per the Form 5500 | $(25517999) |

---

------

**Supplemental Schedule**

**Retirement and Savings Plan for Amgen Manufacturing Limited LLC**

**EIN: 98-0210484 Plan: #001**

**As of December 31, 2025** 

**Schedule H, line 4i – Schedule of Assets (Held at End of Year)**

---

| | | | |
|:---|:---|:---|:---|
| **Identity of Issue** | **Description of Investment** | **Current Value** | **Current Value** |
| Amgen stock\* | Employer Securities | $126196526 |  |
|  |  |  | $126196526 |
| Capital Preservation Asset Class: |  |  |  |
| Wells Fargo Stable Value Fund W\* | Collective Trust Fund | 104631966 |  |
| NT Collective Short Term Investment Fund\* | Collective Trust Fund | 8236750 |  |
| Total Capital Preservation Asset Class |  |  | 112868716 |
| Fixed Income Active Asset Class: |  |  |  |
| Wellington Core Bond Plus Portfolio Collective Investment Trust II\* | Collective Trust Fund | 19786144 |  |
| FIAM Group Trust For Employees Benefit Plan Core Plus Commingled Pool Class W\* | Collective Trust Fund | 19684534 |  |
| BBH Collective Investment Series Trust Series Fund Income Class 1\* | Collective Trust Fund | 19673510 |  |
| NT Collective Aggregate Bond Index Fund / Non Lending\* | Collective Trust Fund | 9168289 |  |
| Total Fixed Income Active Asset Class |  |  | 68312477 |
| Fixed Income Index Asset Class: |  |  |  |
| NT Collective Aggregate Bond Index Fund / Non Lending\* | Collective Trust Fund | 119759185 |  |
| Total Fixed Income Index Asset Class |  |  | 119759185 |
| U.S. Equity Active Asset Class: |  |  |  |
| Nuveen Winslow Large Capital Growth Fund Class C\* | Collective Trust Fund | 19602868 |  |
| Blackrock Instituitional Trust Company Investment Funds Russell 3000 Alpha Tilts Fund F\* | Collective Trust Fund | 15451387 |  |
| Boston Partners CIT Large Capital Value Class E\* | Collective Trust Fund | 13991029 |  |
| NT Collective Russell 3000 Index Fund / Non Lending\* | Collective Trust Fund | 2388133 |  |
| Clean Harbors Inc. | Common and Preferred Stock | 324286 |  |
| Coherent Corporation | Common and Preferred Stock | 302326 |  |
| Ametek Inc. | Common and Preferred Stock | 288666 |  |
| SS&C Technologies Holdings Inc. | Common and Preferred Stock | 288136 |  |
| Waste Connections Inc. | Common and Preferred Stock | 278121 |  |
| Entegris Inc. | Common and Preferred Stock | 262523 |  |
| BWX Technologies Inc. | Common and Preferred Stock | 248371 |  |
| NT Collective Short Term Investment Fund\* | Collective Trust Fund | 214623 |  |
| Huntington Bancshares Inc. | Common and Preferred Stock | 207593 |  |
| Woodward Inc. | Common and Preferred Stock | 201950 |  |
| UGI Corporation | Common and Preferred Stock | 199090 |  |
| Rentokil Initial PLC | Common and Preferred Stock | 184361 |  |
| Charles River Laboratories International Inc. | Common and Preferred Stock | 173348 |  |
| Bio-Techne Corporation | Common and Preferred Stock | 171196 |  |
| Keysight Technologies Inc. | Common and Preferred Stock | 168241 |  |
| Amphenol Corporation Class A | Common and Preferred Stock | 167168 |  |

---

------

Schedule H, line 4i – Schedule of Assets (Held at End of Year) (continued)

---

| | | |
|:---|:---|:---|
| **Identity of Issue** | **Description of Investment** | **Current Value** |
| Ingredion Inc. | Common and Preferred Stock | 165831 |
| Halozyme Therapeutics Inc. | Common and Preferred Stock | 165625 |
| Henry Schein Inc. | Common and Preferred Stock | 161666 |
| Brown & Brown Inc. | Common and Preferred Stock | 159639 |
| Heico Corporation Class A | Common and Preferred Stock | 151458 |
| Dolby Laboratories Inc. | Common and Preferred Stock | 144302 |
| Shift4 Payments Inc. Class A | Common and Preferred Stock | 139856 |
| IDEX Corporation | Common and Preferred Stock | 135412 |
| STERIS plc | Common and Preferred Stock | 133859 |
| LKQ Corporation | Common and Preferred Stock | 120800 |
| Power Integrations Inc. | Common and Preferred Stock | 119059 |
| Prosperity Bancshares Inc. | Common and Preferred Stock | 108434 |
| WEX Inc. | Common and Preferred Stock | 107117 |
| Hexcel Corporation | Common and Preferred Stock | 104199 |
| HealthEquity Inc. | Common and Preferred Stock | 102786 |
| Casella Waste Systems Inc. Class A | Common and Preferred Stock | 97156 |
| Mid-American Apartment Communities Inc. | Common and Preferred Stock | 96404 |
| Allegion PLC | Common and Preferred Stock | 95214 |
| Cabot Corporation | Common and Preferred Stock | 92456 |
| Graco Inc. | Common and Preferred Stock | 88774 |
| RBC Bearings Inc. | Common and Preferred Stock | 79821 |
| Procore Technologies Inc. | Common and Preferred Stock | 78196 |
| First American Financial Corporation | Common and Preferred Stock | 75940 |
| Copart Inc. | Common and Preferred Stock | 74033 |
| Ensign Group Inc. | Common and Preferred Stock | 71945 |
| Federal Signal Corporation | Common and Preferred Stock | 64611 |
| National Retail Properties Inc. | Common and Preferred Stock | 64359 |
| Fabrinet Company | Common and Preferred Stock | 64194 |
| Nova Measuring Instruments | Common and Preferred Stock | 63708 |
| Medpace Holdings Inc. | Common and Preferred Stock | 63466 |
| Bank Ozk | Common and Preferred Stock | 59320 |
| EnPro Inc. | Common and Preferred Stock | 57601 |
| Moelis & Company Class A | Common and Preferred Stock | 54717 |
| SiteOne Landscape Supply Inc. | Common and Preferred Stock | 54557 |
| Paymentus Holdings Inc. Class A | Common and Preferred Stock | 52787 |
| Standex International Corporation | Common and Preferred Stock | 50409 |
| Kadant Inc. | Common and Preferred Stock | 50164 |
| Ollies Bargain Outlet Holdings Inc. | Common and Preferred Stock | 46913 |
| Balchem Corporation | Common and Preferred Stock | 46621 |
| Loar Holdings Inc. | Common and Preferred Stock | 46376 |
| Camtek Limited | Common and Preferred Stock | 46154 |
| CSW Industrials Inc. | Common and Preferred Stock | 45497 |
| Saia Inc. | Common and Preferred Stock | 43754 |
| Everus Construction Group Inc. | Common and Preferred Stock | 43721 |
| Modine Manufacturing Company | Common and Preferred Stock | 43257 |
| CCC Intelligent Solutions Holdings Inc. | Common and Preferred Stock | 42509 |
| ICF International, Inc. | Common and Preferred Stock | 42053 |
| Global-E Online Limited | Common and Preferred Stock | 41669 |
| Markel Corporation Holding Company | Common and Preferred Stock | 40843 |
| Hamilton Lane Inc. Class A | Common and Preferred Stock | 40293 |
| Five Below Inc. | Common and Preferred Stock | 39744 |

---

------

Schedule H, line 4i – Schedule of Assets (Held at End of Year) (continued)

---

| | | | |
|:---|:---|:---|:---|
| **Identity of Issue** | **Description of Investment** | **Current Value** | **Current Value** |
| Clearwater Analytics Holdings Inc. Class A | Common and Preferred Stock | 37410 |  |
| Guidewire Software Inc. | Common and Preferred Stock | 36986 |  |
| XPEL Inc. | Common and Preferred Stock | 35236 |  |
| Certara Inc. | Common and Preferred Stock | 30624 |  |
| Wingstop Inc. | Common and Preferred Stock | 29811 |  |
| RLI Corporation | Common and Preferred Stock | 29559 |  |
| Arhaus Inc. Class A | Common and Preferred Stock | 29101 |  |
| Valvoline Inc. | Common and Preferred Stock | 28915 |  |
| Q2 Holdings Inc. | Common and Preferred Stock | 28215 |  |
| UFP Industries Inc. | Common and Preferred Stock | 27224 |  |
| Novanta Inc. | Common and Preferred Stock | 26416 |  |
| Freshpet Inc. | Common and Preferred Stock | 25712 |  |
| Morningstar Inc. | Common and Preferred Stock | 25208 |  |
| Floor & Decor Holdings Inc. | Common and Preferred Stock | 23869 |  |
| Goosehead Insurance Inc. Class A | Common and Preferred Stock | 22832 |  |
| Trex Company Inc. | Common and Preferred Stock | 21855 |  |
| AAON Inc. | Common and Preferred Stock | 20969 |  |
| Cohen & Steers Inc. | Common and Preferred Stock | 19776 |  |
| Bellring Brands Inc. | Common and Preferred Stock | 16893 |  |
| Vita Coco Company Inc. | Common and Preferred Stock | 8694 |  |
| Pool Corporation | Common and Preferred Stock | 5719 |  |
| Total U.S. Equity Active Asset Class |  |  | 59823719 |
| U.S. Equity Index Asset Class: |  |  |  |
| NT Collective Russell 3000 Index Fund / Non Lending\* | Collective Trust Fund | 226917206 |  |
| Total U.S. Equity Index Asset Class |  |  | 226917206 |
| International Equity Active Asset Class: |  |  |  |
| Dodge & Cox International Stock Fund | Mutual Fund | 27612784 |  |
| Mawer International Equity Collective Investment Trust Class B\* | Collective Trust Fund | 27322286 |  |
| Great Grey Trust Company<br>GQG Partners International Equity <br>CIT Class C\* | Collective Trust Fund | 26952254 |  |
| Wilmington Trust Collective Investment Trust / Jennison International Equity Opportunities CIT Class J\* | Collective Trust Fund | 26817997 |  |
| Mondrian Master CIT Focused All Countries World ex-US Equity\* | Collective Trust Fund | 26740527 |  |
| NT Collective MSCI All Country World Index (ACWI) ex/US Index Fund / Non Lending\* | Collective Trust Fund | 4438045 |  |
| Total International Equity Active Asset Class |  |  | 139883893 |
| International Equity Index Asset Class: |  |  |  |
| NT Collective MSCI All Country World Index (ACWI) ex/US Index Fund / Non Lending\* | Collective Trust Fund | 30357741 |  |
| Total International Equity Index Asset Class |  |  | 30357741 |
| Participant Self-Directed Accounts | Various Investments | 26713652 |  |
|  |  |  | 26713652 |
| Notes Receivable from Participants\* | Interest Rate 4.25% - 9.50% | 18631683 |  |
|  |  |  | 18631683 |

---

------

Schedule H, line 4i – Schedule of Assets (Held at End of Year) (continued)

---

| | | | |
|:---|:---|:---|:---|
| **Identity of Issue** | **Description of Investment** | **Current Value** | **Current Value** |
| Other |  |  |  |
| Tax Reclaims | Cash and Cash Equivalents | 284750 |  |
| ML Vanguard Federal Money Market Forfeiture / Settlement\* | Cash and Cash Equivalents | 54661 |  |
| NT Collective Short Term Investment Fund\* | Collective Trust Fund | 2258 |  |
| Total Other |  |  | 341669 |
| Grand Total |  |  | $929806467 |

---

 <br> \* Indicates party-in-interest

------

**RETIREMENT AND SAVINGS PLAN FOR** 

**AMGEN MANUFACTURING LIMITED LLC**

**INDEX TO EXHIBIT**

<u>[Consent of Independent Registered Public Accounting Firm](amgn-ex231_20251231xpuerto.htm)</u> Exhibit 23.1

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the trustees (or other persons who administer the employee benefit plan) have duly caused this annual report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| | | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Retirement and Savings Plan for Amgen Manufacturing Limited LLC<br> (Name of Plan) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Retirement and Savings Plan for Amgen Manufacturing Limited LLC<br> (Name of Plan) |
| Date: | June 11, 2026 | By: | &nbsp;&nbsp;&nbsp;/s/ PETER H. GRIFFITH |
|  |  |  | &nbsp;&nbsp;&nbsp;Peter H. Griffith |
|  |  |  | &nbsp;&nbsp;Executive Vice President and Chief Financial Officer |
|  |  |  | &nbsp;&nbsp;Amgen Manufacturing Limited LLC |

---

## Exhibit 23.1

**Exhibit 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in the Registration Statements (Form S-8 Nos. 033-47605, 333-144580 and 333-216715) pertaining to the Retirement and Savings Plan for Amgen Manufacturing Limited LLC of Amgen Inc. of our report dated June 11, 2026, with respect to the financial statements and schedule of the Retirement and Savings Plan for Amgen Manufacturing Limited LLC included in this Annual Report (Form 11-K) for the year ended December 31, 2025.

/s/ ERNST & YOUNG LLP

Los Angeles, California

June 11, 2026

<br>